Department of Pathology/Microbiology & Pharmacology, The University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago
Auto-generated profile, based on publicly available information
Bijay Raj Pandit
Department of Pathology/Microbiology & Pharmacology, The University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago
Monoclonal antibodies (mAbs) targeting various pathways in cancer therapy play crucial roles in enhancing the immune system’s ability to recognise and eliminate tumour cells. These therapies are designed to either block inhibitory immune checkpoint pathways or to target specific tumour cell markers for direct destruction. Additionally, mAbs can modulate the tumour microenvironment, enhance antibody-dependent cellular cytotoxicity, and inhibit angiogenesis, further amplifying their therapeutic impact. Below is a summary of monoclonal antibodies targeting key pathways, along with their indications and mechanisms of action, which are reviewed based on therapeutic mechanisms.
Biofilms constitute a significant challenge in the therapy of infectious diseases, offering remarkable resistance to both pharmacological treatments and immunological elimination. This resilience is orchestrated through the regulation of extracellular polymeric molecules, metabolic dormancy, and quorum sensing, enabling biofilms to persist in both clinical and industrial environments. The resulting resistance exacerbates chronic infections and contributes to mounting economic burdens. This review examines the molecular and structural complexities that drive biofilm persistence and critically outlines the limitations of conventional diagnostic and therapeutic approaches. We emphasize advanced technologies such as super-resolution microscopy, microfluidics, and AI-driven modeling that are reshaping our understanding of biofilm dynamics and heterogeneity. Further, we highlight recent progress in biofilm-targeted therapies, including CRISPR-Cas-modified bacteriophages, quorum-sensing antagonists, enzyme-functionalized nanocarriers, and intelligent drug-delivery systems responsive to biofilm-specific cues. We also explore the utility of in vivo and ex vivo models that replicate clinical biofilm complexity and promote translational applicability. Finally, we discuss emerging interventions grounded in synthetic biology, such as engineered probiotic gene circuits and self-regulating microbial consortia, which offer innovative alternatives to conventional antimicrobials. Collectively, these interdisciplinary strategies mark a paradigm shift from reactive antibiotic therapy to precision-guided biofilm management. By integrating cutting-edge technologies with systems biology principles, this review proposes a comprehensive framework for disrupting biofilm architecture and redefining infection treatment in the post-antibiotic era.
31 December 2020 in Journal of Nepal Medical Association
Introduction: Neonatal mortality rate is highest in sub-Saharan Africa and Southern Asia region. The present study is undertaken to find out prevalence of neonatal sepsis, recognize bacterial pathogens, neonatal risk factors, major symptoms, and their antibiotic sensitivity pattern in neonates in tertiary care hospital in southern Nepal. Methods: A descriptive cross-sectional study was carried out in a tertiary care hospital from 2nd January 2017 to 20th February 2018 after approval (Ref: 125/2016-17). The sample size was calculated and convenience sampling was done. Data were collected from hospital records and microbiology laboratory and analyzed by Statistical Package for Social Sciences. Results: Out of 1200 clinically suspected cases, early-onset neonatal sepsis was seen in 290 (79.89%). A positive culture was seen in 363 (30.25%) where maximum bacterial growth was found in 254 (69.98%) males. Preterm gestational age was seen in 265 (73%), low birth weight 284 (78.23%), a vaginal delivery mode in 279 (76.90%), and delivery in hospital in 232 (63.91%). Likewise, Staphylococcus aureus in 229 (63.08%) was found maximum followed by Klebsiella pneumoniae in 48(13.22%). The major symptom observed was Respiratory distress in 245 (20.41%) while culture positive was seen in poor cry in 94 (53.10%). Mainly effective antibiotics against Gram-positive and gram-negative organisms were Linezolid in 250 (94%) and Imipenem in 46 (90.19%), whereas Penicillin-G in 254 (99.21%) and Ampicillin in 38 (94.74%) found resistance towards organisms respectively. Conclusions: The high prevalence of neonatal sepsis in our study reflects a huge challenge to reduce the neonatal mortality rate to 12 by 2030 of Sustainable Development Goals. Bacterial isolates exhibited higher resistance towards commonly used antibiotics.
This systematic review evaluated the effectiveness and side effects of various COVID-19 vaccines, with a focus on Trinidad and Tobago. The Pfizer-BioNTech and Moderna vaccines demonstrated the highest efficacy, particularly against COVID-19 variants, while Janssen and Sinopharm were comparatively less effective. mRNA vaccines, such as Pfizer-BioNTech and Oxford-AstraZeneca, were associated with more frequent and severe side effects, including soreness, fever, and cardiovascular issues. The review also identified significant gaps in the current scientific literature regarding COVID-19 vaccination issues in Trinidad and Tobago. These gaps highlight the need for comprehensive research to address vaccination challenges, including public health communication, equitable access, and local perceptions of vaccine safety. This analysis provides a foundation for developing targeted strategies to improve vaccine effectiveness in the region.
7 February 2024 in Asian Journal of Pharmaceutical and Clinical Research
Objective: This research was carried out from September to March 2023 at the National Medical College and Teaching Hospital with the objective to detect most prominent nosocomial infection causing microorganisms in hospital environment. Methods: A total of 148 environment samples (66 in air samples and 82 surface samples) from different wards were taken from the hospital environment. All the samples were processed following standard microbiological methods. Results: Gram-positive cocci were the most prominent ones followed by Gram-positive bacilli and then Gram-negative bacilli. Among Gram-positive isolates, coagulase-negative staphylococci accounted for 28.84% of the isolates followed by Staphylococcus aureus with 25.76%, Streptococci with 8.23%, and Gram-positive rods with 17.68%. Among Gram-negative isolates, Acinetobacter spp. accounted for 8.08% followed by Escherichia coli with 1.43% and Klebsiella spp with 0.35%. Among fungal isolates, yeasts were found in higher number with 9.59% in comparison to Aspergillus spp. All Gram-positive isolates were sensitive to vancomycin. Among Gram-negative isolates, E. coli showed the highest susceptibility to amikacin with 85%, Klebsiella spp, and Acinetobacter spp showed the higher degree of susceptibility to ciprofloxacin with 80% and 74.2% respectively. Conclusions: The high incidence of similar types of bacterial isolates detection in the hospital environment suggests that the environment surrounding the hospital may be significantly contaminated with nosocomial pathogens and could represent a major mode of transmission to patients.
Salmonella infections in poultry represent a significant threat to public health and contribute to substantial economic losses within the agricultural sector. In response to these challenges, this study explored an innovative dual control strategy integrating the use of indigenous plant-based bacterial attenuation with targeted immunotherapy using egg yolk-derived immunoglobulin Y (IgY) antibodies. Garlic (Allium sativum) and onion (Allium cepa) extracts were employed to attenuate virulent strains of Salmonella enterica, resulting in a notable reduction in bacterial viability during in vitro assays. Following oral vaccination with the attenuated strains, chickens mounted a robust immune response, characterised by the production of high titres of anti-Salmonella IgY antibodies, as measured by ELISA. Functional assays demonstrated that these antibodies possessed strong agglutination activity against homologous Salmonella strains, highlighting their utility in passive immunisation protocols. Safety assessments confirmed the vaccine’s non-pathogenic profile, while immunogenicity trials showed consistent antibody production across vaccinated flocks. This dual modality—combining natural antimicrobial agents with specific IgY-based immunotherapy—offers a sustainable, low-cost alternative to antibiotics, with the potential to reduce zoonotic transmission, enhance poultry welfare, and support antimicrobial stewardship in animal husbandry.